View of Metabolic derangements among the Schizophrenia patients consuming second generation atypical antipsychotics-Olanzapine and Aripiprazole: a randomised controlled trial.

Return to Article Details Metabolic derangements among the Schizophrenia patients consuming second generation atypical antipsychotics-Olanzapine and Aripiprazole: a randomised controlled trial. Download Download PDF